从资金流向上来看，当日生物制品板块主力资金净流出4.28亿元，游资资金净流入1525.3万元，散户资 金净流入4.13亿元。生物制品板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月16日生物制品板块较上一交易日下跌1.2%，万泽股份领跌。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。生物制品板块个股涨跌见下表： ...

Group 1 - The stock price of Jindike (688670.SH) fell by 7.02%, closing at 22.26 yuan, indicating it is currently in a state of decline since its IPO [1] - Jindike was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 2, 2021, with an initial public offering (IPO) of 22 million shares at a price of 55.18 yuan per share [1] - The total amount raised from the IPO was 1.214 billion yuan, with a net amount of 1.136 billion yuan, which is 464 million yuan less than the originally planned net amount of 1.6 billion yuan [1] Group 2 - The company initially intended to raise 1.6 billion yuan for projects including the construction of a new facility for a quadrivalent influenza virus vaccine, innovative vaccine research and development, working capital, and repayment of bank loans [1] - The total issuance costs for the IPO amounted to 78.2839 million yuan, with underwriting and sponsorship fees accounting for 64.3399 million yuan [1] - Citic Securities' subsidiary, Citic Securities Investment Co., Ltd., participated in the investment with a stake of 4%, acquiring 880,000 shares for 48.5584 million yuan, with a lock-up period of 24 months [1] Group 3 - On May 19, 2023, Jindike announced its 2022 annual profit distribution plan, which included a cash dividend of 0.2 yuan per share and a capital reserve increase of 0.4 shares per share [2] - The total cash dividend distributed amounted to 17.6 million yuan, and the share capital increase resulted in an additional 35.2 million shares, bringing the total share capital to 123.2 million shares [2] - Key dates for the distribution included the equity registration date on May 25, 2023, the ex-dividend date on May 26, 2023, and the cash dividend payment date also on May 26, 2023 [2]

Core Viewpoint - The company is focusing on expanding its overseas business, particularly in European countries, including some EU nations, and has achieved a significant milestone by passing the EU Quality Authorization audit, which will facilitate further market expansion [1] Group 1 - The company's overseas business is primarily concentrated in Europe and certain EU countries [1] - The proportion of the company's overseas business has been gradually increasing in recent years [1] - The company has passed the EU Quality Authorization audit, which is expected to accelerate its expansion into the European and international markets by September 2025 [1]

正海生物公告，控股股东、实际控制人秘波海先生将其持有的1,600万股公司股份办理了解除质押业 务，占其所持股份比例26.25%，占公司总股本比例8.89%。此次解除质押的股份起始日为2022年6月22 日，解除日期为2025年12月15日，质权人为烟台银行股份有限公司开发支行。截至本公告披露日，秘波 海先生及其一致行动人累计质押股份为0股。 ...

无锡惠山经开区企业无锡市申瑞生物制品有限公司与复旦大学附属中山医院联合申报的"心血管疾病围 术期急性肾损伤预测和干预研究"项目，近日正式获批"2025年度癌症、心脑血管、呼吸和代谢性疾病防 治研究国家科技重大专项"(2025ZD0547600)。 此次合作，是产学研深度融合的生动实践，更是双方立足国家战略需求、深耕重大疾病防治领域的责任 担当。复旦大学附属中山医院作为项目牵头单位，将发挥其在医学科研、临床研究及项目统筹方面的深 厚积淀，负责组织各参与单位推进研究内容，确保项目顺利实施。申瑞生物作为联合单位，将推动项目 成果的市场落地与临床推广应用，助力研究技术从实验室走向实际医疗场景。 企业 目前，惠山经开区已集聚申瑞生物、泛生子基因、吐露港生物等一批代表性企业，技术拓展至二代深度 测序、基因芯片、数字PCR、肿瘤早筛、CRISPR等精准医疗前沿领域。依托惠山生命园，惠山经开区 将坚持科学规划与前瞻布局，持续推进营商环境建设，完善以创新和金融为驱动的生命健康企业培育体 系，深入推进覆盖研发、孵化、中试到产业化的生命科技全产业链建设。 扬子晚报/紫牛新闻记者张建波 校对盛媛媛 无锡市申瑞生物制品有限公司位于无锡 ...

皮匠嘴股票 "今天A股三大指数震荡调整，沪指冲高回落，创业板指低开低走。截至收盘，沪指报3867.92点，跌 0.55%，成交7646亿元；深证成指报13112.09点，跌1.10%，成交10088亿元；创业板指报3137.80点，跌 1.77%，成交4721亿元。沪深两市全天成交额17734亿元。行业板块涨跌互现，保险、商业百货、食品 饮料、化纤行业、贵金属板块涨幅居前，船舶制造、能源金属、半导体、生物制品、消费电子板块跌幅 居前。整体是一个倒V型走势。"牛皮匠说。 "受商务部、中国人民银行、金融监管总局联合发布《关于加强商务和金融协同更大力度提振消费的通 知》的利好刺激，消费板块逆市掀涨停潮。而近两周市场最强的航天板块开盘回调，航天发展 （000547）和航天动力（600343）一度杀到跌停附近，随后航天机电（600151）上板稳住局势，板块开 始回流。航天板块出现分歧滞涨高位，而上周较强的芯片、通信、科创板却出现明显的亏钱效应。"犟 皮匠说。 "今天涨跌家数大致是各一半，还有60多家涨停，指数没有行情，但板块和个股却有行情。上周五买的 争光股份（301092）逆市冲高，我趁机获利了结，这只股票算是争了个 ...

Investment Rating - The report maintains a "Positive" investment rating for the healthcare sector [14] Core Insights - The non-pharmaceutical sector is facing performance pressure in 2025 due to price reductions from centralized procurement, medical insurance cost control, and the closure of retail pharmacies. However, companies are leveraging overseas expansion and innovation to achieve growth [4][9] - For 2026, the domestic fundamentals are expected to improve, with companies seeking new growth points primarily through overseas expansion and innovation, particularly in insulin and medical devices [9] - The report highlights that the insulin market is stabilizing post-centralized procurement, with significant overseas opportunities for leading companies like Mindray Medical and Ganli Pharmaceutical [10][24] - The focus on innovation in traditional Chinese medicine and medical devices is expected to create alpha opportunities for individual stocks [9][11] Summary by Sections Non-Pharmaceutical Sector - The non-pharmaceutical sector is under pressure but has opportunities through overseas expansion and innovation. Insulin and medical devices are key areas for long-term growth [4][9] - Companies like Mindray Medical and Ganli Pharmaceutical are beginning to realize overseas revenue, indicating a significant long-term market potential [9] Biopharmaceuticals - The report prioritizes insulin, with ongoing attention to blood products and vaccines. The insulin market is stabilizing, and companies are focusing on innovation and business development [10][24] - The report notes that the insulin market in developed countries is valued at $13.2 billion, with significant growth potential in emerging markets [24] Traditional Chinese Medicine - The focus is on innovation and the basic drug catalog, which is crucial for accelerating drug sales and enhancing market presence [11][12] - The report anticipates a recovery in performance due to early flu outbreaks and emphasizes the importance of retail pharmacy sales [11] Medical Devices - The report indicates that the medical device sector is at a turning point, with overseas revenue for leading companies expected to exceed 50% in 2025 [12] - The report suggests focusing on low-value consumables and in vitro diagnostics as key growth areas [12] Vaccines - The vaccine sector is currently facing challenges, with price reductions and low demand impacting sales. However, there are ongoing developments in innovative vaccines that warrant attention [39][40] - The report highlights the importance of tracking clinical progress and market performance of major vaccine candidates [40]

百克生物本次上市发行费用为1.05亿元，其中，保荐机构、主承销商中信证券股份有限公司和联席 主承销商国泰君安证券股份有限公司获得承销保荐费9004.06万元。 本次发行最终战略配售数量为825.61万股，约占发行总数量的20.00%，与初始战略配售数量的差 额744股回拨至网下发行。依据《上海证券交易所科创板股票发行与承销业务指引》第十八条规定，本 次发行保荐机构相关子公司中信证券投资有限公司最终获配股份数量为165.06万股，获配金额6000.00 万元。 (责任编辑：徐自立) 中国经济网北京12月15日讯 百克生物（688276.SH）今日收报19.37元，跌幅2.42%。 百克生物于2021年6月25日在上交所科创板上市，公司公开发行股票数量为4128.41万股，占本次 发行后总股本的10.00%，发行价格为36.35元/股，保荐机构为中信证券股份有限公司，保荐代表人为 董芷汝、朱绍辉。目前该股股价处于破发状态。 百克生物本次募集资金总额为15.01亿元，扣除发行费用后，实际募集资金净额为13.96亿元。百 克生物最终募集资金净额比原计划少2.85亿元。百克生物于2021年6月21日披露的招股说明书显示 ...

证券之星消息，12月15日生物制品板块较上一交易日下跌1.28%，康乐卫士领跌。当日上证指数报收于 3867.92，下跌0.55%。深证成指报收于13112.09，下跌1.1%。生物制品板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日生物制品板块主力资金净流出4.47亿元，游资资金净流入1.36亿元，散户资金 净流入3.12亿元。生物制品板块个股资金流向见下表： ...

格隆汇12月15日丨生物股份(600201.SH)在投资者互动平台表示，公司狂犬疫苗和猫三联疫苗均在售。 猫三联疫苗通过线上平台与线下联动，前三季度销量取得较大幅增长。 ...